---
title: "Armata Pharmaceuticals, Inc. (ARMP.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ARMP.US/overview.md"
symbol: "ARMP.US"
name: "Armata Pharmaceuticals, Inc."
parent: "https://longbridge.com/en/quote/ARMP.US.md"
datetime: "2026-04-06T11:18:18.809Z"
locales:
  - [en](https://longbridge.com/en/quote/ARMP.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ARMP.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ARMP.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ARMP.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ARMP.US/overview.md)


# Armata Pharmaceuticals, Inc. (ARMP.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 5005 McConnell Avenue, Los Angeles, California, United States |
| Website | [www.armatapharma.com](https://www.armatapharma.com) |

## Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

## Key Executives

| Name | Title |
|------|-------|
| Deborah L. Birx | CEO & Director |
| Robin C. Kramer | Independent Chairman of the Board |
| David D. House | Senior VP of Finance & Principal Financial Officer |
| Pierre Kyme | Chief Business Officer |
| Peter Hubbard | Vice President of Operations |
| Bani Tchekanova | Head of Regulatory Strategy & Operations |
| Joseph M. Patti | Independent Director |
| Sarah J. Schlesinger | Independent Director |
| James Bader | Member of C16G2 Clinical Advisory Board |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Innoviva, Inc. | 68.45% | 2026-01-23 |
| The Vanguard Group, Inc. | 0.98% | 2025-12-31 |
| Deborah L. Birx | 0.58% | 2026-03-14 |
| 683 Capital Management, LLC | 0.38% | 2025-12-31 |
| Geode Capital Management, LLC | 0.30% | 2025-12-31 |
| Edgewood Management LLC | 0.27% | 2025-12-31 |
| BlackRock, Inc. | 0.20% | 2025-12-31 |
| Renaissance Technologies LLC | 0.19% | 2025-12-31 |
| Mina Pastagia | 0.17% | 2025-04-17 |
| State Street Global Advisors, Inc. | 0.14% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Biotechnology | 5174000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Armata Pharmaceuticals, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Biotechnology",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 5174000 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**